A REVIEW ON TRANSLATIONAL PERSPECTIVE AND EFFICACY OF DIFFERENT ENGINEERED THERAPEUTIC ANTIBODIESAbstract
From bench to bedside, clinical research had always played as a convenient tool in the field of cancer biology to inquire about the effectiveness of different anticancer drugs on different human-derived cancer cell lines. According to the American Cancer Society, nearly 4000 new cases and 1600 deaths predicted in 2019 in the United States. Besides, to these alarming statistics, rising cost and health-related complications associated with treatments had made the research of cell lines on the anticancer drug more relevant. This article providing a comprehensive review of cancer, advanced development of the anticancer drugs, and a brief inference on progression-free survival rate (PFS) of the following anticancer and engineered monoclonal antibody drugs are discussed.
C. Roy and T. Chakraborty *
Department of Biotechnology, Guru Nanak Institute of Pharmaceutical Science and Technology, Panihati, Kolkata, West Bengal, India.
03 September 2019
21 December 2020
02 March 2020
01 June 2020